Effect of bevacizumab on human corneal endothelial cells: a six-month follow-up study.
OBJECTIVE
To assess in vivo corneal endothelial changes occurring over a six-month period after the intravitreal injection of bevacizumab (Avastin; Genentech Inc, San Francisco, California, USA) in patients with various macular diseases.


METHODS
Prospective case series.


METHODS
A total of 50 eyes from 50 consecutive patients received an intravitreal injection of 2.5 mg intravitreal bevacizumab. Specular microscopy, including central corneal thickness (CCT) and endothelial cell count, was performed on each patient for both eyes before injection and one day, seven days, three months, and six months after injection. The CCT at one and seven days was measured to evaluate the acute corneal endothelial damage; endothelial cell count at three and six months was used to estimate chronic corneal endothelial change.


RESULTS
All patients completed six months of follow-up. There was no significant difference in corneal thickness change between treated and nontreated eyes before injection or one and seven days after injection (P = .53, .34, and .87, respectively). There was also no difference in the treated eyes before injection and one and seven days after injection (P = .94). Long-term evaluation revealed that there was no significant difference in the corneal endothelial cell density of treated and nontreated eyes before injection and at three and six months after injection (P = .76, .13, and .22, respectively). There was also no difference in the treated eyes before injection and at three and six months after injection (P = .73).


CONCLUSIONS
The intravitreal injection of 2.5 mg bevacizumab seemed to have no harmful effects on the corneal endothelium.
Chiang
Chun-Chi
CC
Department of Ophthalmology, China Medical University Hospital, Taichung, Taiwan.
Chen
Wen-Lu
WL
Lin
Jane-Ming
JM
Tsai
Yi-Yu
YY
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002452:Cell Count; D003315:Cornea / Q000187:drug effects / Q000473:pathology; D004728:Endothelium, Corneal / Q000187:drug effects* / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008266:Macula Lutea; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012164:Retinal Diseases / Q000188:drug therapy* / Q000473:pathology*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab